{"id":"metformin-glyburide-and-insulin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Gastrointestinal disturbance (metformin)"},{"rate":null,"effect":"Weight gain (insulin, glyburide)"},{"rate":null,"effect":"Lactic acidosis (metformin, rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metformin is a biguanide that decreases hepatic gluconeogenesis and improves insulin sensitivity. Glyburide is a sulfonylurea that stimulates beta cells to release endogenous insulin. Insulin provides exogenous glucose control. Together, these agents target multiple pathways in diabetes pathophysiology—hepatic glucose output, endogenous insulin secretion, and peripheral glucose uptake.","oneSentence":"This combination therapy addresses type 2 diabetes through three complementary mechanisms: metformin reduces hepatic glucose production, glyburide stimulates pancreatic insulin secretion, and insulin provides direct glucose-lowering action.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:20:57.168Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT03029702","phase":"PHASE4","title":"Metabolic Analysis for Treatment Choice in Gestational Diabetes Mellitus","status":"COMPLETED","sponsor":"Maisa N. Feghali, MD","startDate":"2018-02-28","conditions":"Gestational Diabetes, Diabetes, Gestational, Pregnancy in Diabetes","enrollment":54},{"nctId":"NCT01107717","phase":"PHASE4","title":"Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2009-01","conditions":"Diabetes","enrollment":318},{"nctId":"NCT05161429","phase":"","title":"BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-07-01","conditions":"Diabetes Mellitus, Type 2","enrollment":550000},{"nctId":"NCT01215331","phase":"PHASE3","title":"Gestational Diabetes: Insulin or Oral Hypoglycemic Agents?","status":"COMPLETED","sponsor":"Université de Sherbrooke","startDate":"2010-08","conditions":"Gestational Diabetes Mellitus","enrollment":73},{"nctId":"NCT00232583","phase":"NA","title":"Preservation of Beta-cell Function in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2003-11","conditions":"Type 2 Diabetes Mellitus","enrollment":58},{"nctId":"NCT01357135","phase":"","title":"An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-07-15","conditions":"Type 2 Diabetes Mellitus","enrollment":3453},{"nctId":"NCT01798706","phase":"PHASE3","title":"Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":"Type 2 Diabetes","enrollment":350},{"nctId":"NCT02080377","phase":"PHASE3","title":"A Feasibility Study Looking at the Use of Glibenclamide and metfoRmin Versus stAndard Care in gEstational diabeteS","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2014-07","conditions":"Pregnancy, Gestational Diabetes","enrollment":23},{"nctId":"NCT02476760","phase":"","title":"Incretin-based Drugs and Acute Pancreatitis","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":1417914},{"nctId":"NCT01944618","phase":"","title":"forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2013-10","conditions":"Type 2 Diabetes","enrollment":5000},{"nctId":"NCT02456428","phase":"","title":"Incretin-based Drugs and the Risk of Heart Failure","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Type 2 Diabetes Mellitus","enrollment":1499650},{"nctId":"NCT02607410","phase":"PHASE4","title":"Sitagliptin (DPP-4 Inhibitor) and NPH Insulin in Patients With T2D","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2010-01","conditions":"Type 2 Diabetes Mellitus","enrollment":40},{"nctId":"NCT01998113","phase":"","title":"Glyburide and Metformin for the Treatment of Gestational Diabetes Mellitus. Systematic Review","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2013-03","conditions":"Gestational Diabetes Mellitus","enrollment":2509},{"nctId":"NCT01584232","phase":"PHASE3","title":"A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-04","conditions":"Type 2 Diabetes Mellitus","enrollment":361},{"nctId":"NCT00494312","phase":"PHASE4","title":"Safety Study of Pioglitazone Compared To Glyburide on Liver Function","status":"COMPLETED","sponsor":"Takeda","startDate":"2000-10","conditions":"Diabetes Mellitus, Liver","enrollment":2120},{"nctId":"NCT00935805","phase":"","title":"Glycemic And Blood Pressure Control In Type 2 Diabetes, In A Primary Care Unit: A Staged Management Strategy","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2006-07","conditions":"Diabetes Mellitus, Arterial Hypertension","enrollment":124},{"nctId":"NCT01068860","phase":"PHASE2","title":"To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-02","conditions":"Type 2 Diabetes Mellitus, Impaired Glucose Tolerance","enrollment":246},{"nctId":"NCT00046462","phase":"PHASE3","title":"Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment","status":"COMPLETED","sponsor":"Sanofi","startDate":"2001-11","conditions":"Diabetes Mellitus","enrollment":240},{"nctId":"NCT00347100","phase":"PHASE4","title":"Insulin Glargine in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-06","conditions":"Diabetes Mellitus, Type 2","enrollment":387},{"nctId":"NCT00371306","phase":"NA","title":"Comparison of Glucovance to Insulin for Diabetes During Pregnancy","status":"UNKNOWN","sponsor":"Regional Obstetrical Consultants","startDate":"2002-09","conditions":"Gestational Diabetes, Type 2 Diabetes, Pregnancy","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Metformin, glyburide and insulin","genericName":"Metformin, glyburide and insulin","companyName":"Université de Sherbrooke","companyId":"universit-de-sherbrooke","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination therapy addresses type 2 diabetes through three complementary mechanisms: metformin reduces hepatic glucose production, glyburide stimulates pancreatic insulin secretion, and insulin provides direct glucose-lowering action. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}